1. Field assessment of BinaxNOW antigen tests as COVID-19 treatment entry point at a community testing site in San Francisco during evolving omicron surges.
- Author
-
John Schrom, Carina Marquez, Chung-Yu Wang, Aditi Saxena, Anthea M Mitchell, Salu Ribeiro, Genay Pilarowski, Robert Nakamura, Susana Rojas, Douglas Black, Maria G Contreras Oseguera, Edgar Castellanos Diaz, Joselin Payan, Susy Rojas, Diane Jones, Valerie Tulier-Laiwa, Aleks Zavaleta, Jacqueline Martinez, Gabriel Chamie, Carol Glaser, Kathy Jacobson, Maya Petersen, Joseph DeRisi, and Diane V Havlir
- Subjects
Medicine ,Science - Abstract
COVID-19 oral treatments require initiation within 5 days of symptom onset. Although antigen tests are less sensitive than RT-PCR, rapid results could facilitate entry to treatment. We collected anterior nasal swabs for BinaxNOW and RT-PCR testing and clinical data at a walk-up, community site in San Francisco, California between January and June 2022. SARS-CoV-2 genomic sequences were generated from positive samples and classified according to subtype and variant. Monte Carlo simulations were conducted to estimate the expected proportion of SARS-CoV-2 infected persons who would have been diagnosed within 5 days of symptom onset using RT-PCR versus BinaxNOW testing. Among 25,309 persons tested with BinaxNOW, 2,799 had concomitant RT-PCR. 1137/2799 (40.6%) were SARS-CoV-2 RT-PCR positive. We identified waves of predominant omicron BA.1, BA.2, BA.2.12, BA.4, and BA.5 among 720 sequenced samples. Among 1,137 RT-PCR positive samples, 788/1137 (69%) were detected by BinaxNOW; 94% (669/711) of those with Ct value
- Published
- 2023
- Full Text
- View/download PDF